Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025

Aligos Therapeutics, Inc.

Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.
Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.
Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.
THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.
Lesley Ann Calhoun promoted to EVP, COO and CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.